Mesothelin expression were observed in mesothelioma (two of two patients, 100.0 %), head and neck cancer (two of two patients, 100.0 %), small intestine cancer (one of one patient, 100.0 %), pancreatic adenocarcinoma (four of five patients, 80.0 %), colorectal cancer (10 of 19 patients, 52.6 %), and biliary cancer (four of eight patients, 50.0 %). Here, MSLN is linked to pancreatic adenocarcinoma.